Anteris Technologies Global Corp (ASX: AVR) Share Price and News

Price

$7.50

Movement

0.80 (-9.64%)

as at 2 May - Closed (20 mins delayed)

52 Week Range

$4.26 - $21.70

 
1 Year Return

-64.79%

Anteris Technologies Global Corp Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $270.47 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 36.81 million
Earnings per share -3.767
Dividend per share N/A
Year To Date Return -9.31%
Earnings Yield N/A
Franking -
Share Price

$7.50

Day Change

0.80 (-9.64%)

52 Week Range

$4.26 - $21.70

Yesterday's Close

$8.30

Today's Open

$7.99

Days Range

$7.50 - $7.99

Volume

30,649

Avg. Volume (1 month)

38,852

Turnover

$232,790

as at 2 May - Closed

  • Anteris Technologies Global Corp (ASX: AVR)
    Latest News

    a woman
    Investing

    Why these 4 ASX shares got smashed today

    Aconex Ltd (ASX:ACX) and three other shares finished the week with a disappointing drop. Here’s why they dropped…

    Read more »

    a woman
    Investing

    Admedus Ltd plunges 15%: Should you participate in its capital raising?

    Junior biotech Admedus Ltd (ASX:AHZ) is raising funds again, but is it in your best interests to participate?

    Read more »

    a woman
    Investing

    5 small-cap shares I actually bought with $5,000

    Here's why I own shares in Lifehealthcare Group Ltd (ASX:LHC), Nearmap Ltd (ASX:NEA), and Yellow Brick Road Holdings Ltd (ASX:YBR).

    Read more »

    a woman
    Investing

    Here's why these 4 ASX shares are jumping higher today

    Regis Resources Limited (ASX:RRL) is one of 4 shares rocketing higher despite the S&P/ASX 200 (Index:^AXJO) (ASX:XJO) falling today. Here's…

    Read more »

    a woman
    Investing

    Why the Admedus Ltd share price is 14% higher today

    Biotech company Admedus Ltd (ASX:AHZ) shares surge higher following the release of its fourth quarter report. Is it time to…

    Read more »

    a woman
    Investing

    Why these 4 stocks are going gangbusters today

    Admedus Ltd (ASX:AHZ), Resapp Health Ltd (ASX:RAP) and Ziptel Ltd (ASX:ZIP) shares are climbing today.

    Read more »

    a woman
    Investing

    Want to buy the hottest of hot biotechs?

    CSL Limited (ASX:CSL) has many times the budget, and consequently many times the potential, of small would-be biotech success stories.

    Read more »

    a woman
    Investing

    Why these 4 ASX shares are sinking today

    Admedus Ltd (ASX:AHZ) and Donaco International Ltd (ASX:DNA) are among today's big fallers.

    Read more »

    a woman
    Investing

    Why the Admedus Ltd share price is crashing today

    Admedus Ltd (ASX:AHZ) shares are down 10% today.

    Read more »

    a woman
    Investing

    Why these 4 ASX shares are rocketing higher today  

    Ademdus Ltd (ASX:AHZ) and Select Harvests Limited (ASX:SHV) are among today's big winners.

    Read more »

    a woman
    Investing

    Here's why these 4 shares crashed on the market today

    Could there be worse to come for Super Retail Group Ltd (ASX:SUL), IPH Ltd (ASX:IPH), Netcomm Wireless Ltd (ASX:NTC), and…

    Read more »

    a woman
    Investing

    Here's why these 4 shares crashed on the market today

    Is there worse to come for Monadelphous Group Limited (ASX:MND), Admedus Ltd (ASX:AHZ), WHITEHAVEN COAL LIMITED (ASX:WHC), and Select Harvests…

    Read more »

    AVR ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    30th Apr 2025 2025-04-30T08:59:48 SEC Form 10-K/AYesNo8:59am34481k
    29th Apr 2025 2025-04-29T09:43:32 Notification of cessation of securities - AVRYesNo9:43am515k
    7th Apr 2025 2025-04-07T13:03:00 Application for quotation of securities - AVRYesNo1:03pm921k
    7th Apr 2025 2025-04-07T13:00:55 Notification of cessation of securities - AVRYesNo1:00pm618k
    2nd Apr 2025 2025-04-02T15:17:23 Statement of CDIs on issue - AVRYesNo3:17pm517k
    31st Mar 2025 2025-03-31T09:26:43 Clinical Milestone - 100 patients treated with DurAVR THVYesNo9:26am2205k
    27th Mar 2025 2025-03-27T18:54:08 Cleansing NoticeYesNo6:54pm2209k
    27th Mar 2025 2025-03-27T18:49:53 Application for quotation of securities - AVRYesNo6:49pm1127k
    27th Mar 2025 2025-03-27T18:41:48 Notification regarding unquoted securities - AVRYesNo6:41pm819k
    21st Mar 2025 2025-03-21T10:20:26 Change of Directors' Interest NoticeYesNo10:20am9324k

    About Anteris Technologies Global Corp

    Anteris Technologies Ltd. is a structural heart company, researches, develops, commercializes, and distributes various medical technologies and devices. It manufactures, distributes, and sells ADAPT & DurAVR regenerative tissue products, and researches and develops regenerative medicine and immunotherapies. The company was founded on June 23, 1999 and is headquartered in Toowong, Australia.

    AVR Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    02 May 2025 $7.50 $-0.80 -9.64% 30,649 $7.99 $7.99 $7.50
    01 May 2025 $8.30 $-0.25 -2.92% 37,616 $8.55 $8.75 $8.00
    30 Apr 2025 $8.55 $0.55 6.88% 19,530 $8.00 $8.65 $8.00
    29 Apr 2025 $8.00 $0.02 0.25% 9,371 $8.10 $8.20 $7.87
    28 Apr 2025 $7.98 $0.48 6.40% 104,296 $7.55 $8.40 $7.51
    24 Apr 2025 $7.50 $1.88 33.45% 47,415 $6.58 $7.85 $6.58
    23 Apr 2025 $5.62 $0.74 15.16% 10,334 $5.20 $5.78 $5.20
    22 Apr 2025 $4.88 $0.30 6.55% 21,222 $4.63 $4.99 $4.63
    17 Apr 2025 $4.58 $-0.45 -8.95% 43,589 $4.99 $4.99 $4.55
    16 Apr 2025 $5.03 $0.63 14.32% 28,008 $4.75 $5.16 $4.75
    15 Apr 2025 $4.40 $-0.20 -4.35% 49,023 $4.52 $4.58 $4.26
    14 Apr 2025 $4.60 $-0.25 -5.15% 28,001 $4.85 $4.85 $4.60
    11 Apr 2025 $4.85 $-0.55 -10.19% 20,263 $4.85 $5.00 $4.65
    10 Apr 2025 $5.40 $0.88 19.47% 14,518 $5.20 $5.50 $5.20
    09 Apr 2025 $4.52 $-0.63 -12.23% 58,569 $4.80 $5.10 $4.51
    08 Apr 2025 $5.15 $-0.15 -2.83% 14,926 $5.40 $5.41 $5.11
    07 Apr 2025 $5.30 $-0.30 -5.36% 29,151 $5.40 $5.42 $4.78
    04 Apr 2025 $5.60 $-0.30 -5.08% 129,517 $5.80 $5.90 $5.38
    03 Apr 2025 $5.90 $0.29 5.17% 5,691 $5.81 $6.00 $5.80

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    19 Jun 2024 Stephen (Steve) Denaro Issued 50,000 $950,000
    Issue of options.
    19 Jun 2024 John Seaberg Issued 75,000 $1,425,000
    Issue of options.
    19 Jun 2024 Wayne Paterson Issued 300,000 $5,700,000
    Issue of options.
    19 Jun 2024 Wenyi Gu Issued 50,000 $950,000
    Issue of options.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Stephen (Steve) Denaro Company SecretaryNon-Executive Director Oct 2018
    Mr Denaro has been providing company secretarial services to other ASX-listed companies since 1994 and serves as a director and sole shareholder of Trio Business Intermediaries Pty Ltd, a business consulting company, specialising in restructuring, corporate governance, directorship and company secretarial services, through which he provides these and other services. Mr Denaro has over 25 years of experience in mergers and acquisitions, business valuations, accountancy services, and income tax compliance gained from positions as Company Secretary and Chief Financial Officer of public companies and with chartered accountancy firms in Australia and the United Kingdom. He is chair of risk management committee.
    Mr John Seaberg Non-Executive ChairmanNon-Executive Director Nov 2024
    Mr Seaberg has been serving as Board Chair of Preceptis Medical Inc since 2016 and Phraxis Medical Inc since 2009. He was Executive VP at Cedar Point Capital, a broker-dealer focused on healthcare investment from June 2015 through December 31, 2023. From 2008 until 2012, Mr Seaberg was Chair of Synovis Inc., a NASDAQ-listed manufacturer of medical device and bio scaffold tissue products which was acquired by Baxter, and, from 2007 until 2014, was Co-Founder, Chair and Chief Executive Officer of NeoChord Inc., a company commercialising technology developed at the Mayo Clinic for repair of the mitral valve via minimally invasive techniques. From 1996 to 2006, Mr Seaberg served at Guidant Corp. (subsequently acquired by Boston Scientific Corp.) where he held executive level positions, including Director of Marketing for Cardiac Rhythm Management, Vice President of Sales for Cardiac Surgery and Vice President of Sales for Cardiac Rhythm Management. In addition, Mr Seaberg was co-Founder, President and Chief Executive Officer of ACIST Medical, from 1991 to 1995. He is member of risk management committee.
    Mr Wayne Paterson Chief Executive OfficerManaging Director Feb 2016
    Mr Paterson held senior positions at Merck KGaA (Merck), a science and technology company, from 2005 to 2013, including as President of Europe, Canada and Australia, President of Emerging Markets, President of Japan and President of Cardiovascular Medicine. From 1999 until 2005, Mr Paterson served at Roche Pharmaceuticals, a multinational healthcare company, in several senior positions, including as Head of Pharmaceuticals in Roche's South Korean operation and Head of Commercial Operations for Roche China.
    Dr Wenyi Gu Non-Executive Director Nov 2024
    Dr Gu is currently guest professor with several Chinese institutes and universities. Since January 2017, Dr Gu has been working as a Research Fellow for the Australian Institute for Bioengineering and Nanotechnology at the University of Queensland. In addition, from April 2021 to March 2023, Dr Gu was the Chief Scientific Officer of Guangzhou Gillion Biotherapeutics Ltd, a biotechnology company. From 2006 to 2009, he held a Perter Doherty Fellowship and was supported by the National Health and Medical Research Council to work at Harvard Medical School as a visiting research fellow. Dr Gu is member of risk management committee.
    Mr David St Denis Chief Operating OfficerPresidentNon-Executive director Mar 2025
    Mr Denis, has served as Chief Operating Officer of the Company since July 2017 and the Chief Executive Officer of v2vmedtech, inc. since April 2023. Mr St Denis also served as Chief Financial Officer of v2vmedtech from April 2023 to September 2023. Prior to his appointment as Chief Operating Officer of the Company, Mr St Denis served as Head of Commercial Operations for Europe and Canada at Merck since 2013, and prior to that served as Head of Operations for Emerging Markets at Merck since 2008. In addition, Mr St Denis had held multiple leadership roles at Millennium Pharmaceuticals, Inc, now Takeda Pharmaceutical Company, from 1996 to 2006, and provided strategic consulting services to such company from 2006 to 2008.
    Matthew McDonnell Chief Financial Officer
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    N/A 0 0.00%

    Profile

    since

    Note